XML 42 R29.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 2,764 | $ 3,650 | $ 6,352 | $ 7,166
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,966 | 2,695 | 4,609 | 5,274
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 798 | 955 | 1,743 | 1,892
Orthopaedics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 894 | 1,273 | 2,116 | 2,523
Orthopaedics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 623 | 874 | 1,475 | 1,724
Orthopaedics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 271 | 399 | 641 | 799
Orthopaedics | Knees |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 241 | 440 | 673 | 879
Orthopaedics | Knees | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 179 | 324 | 501 | 644
Orthopaedics | Knees | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 62 | 116 | 172 | 235
Orthopaedics | Hips |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 216 | 343 | 532 | 679
Orthopaedics | Hips | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 140 | 219 | 341 | 432
Orthopaedics | Hips | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 76 | 124 | 191 | 247
Orthopaedics | Trauma and Extremities |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 330 | 394 | 722 | 790
Orthopaedics | Trauma and Extremities | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 208 | 252 | 468 | 506
Orthopaedics | Trauma and Extremities | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 122 | 142 | 254 | 284
Orthopaedics | Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 107 | 96 | 189 | 175
Orthopaedics | Other | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 96 | 79 | 165 | 142
Orthopaedics | Other | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 11 | 17 | 24 | 33
MedSurg |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,324 | 1,601 | 2,946 | 3,128
MedSurg | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,004 | 1,287 | 2,298 | 2,508
MedSurg | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 320 | 314 | 648 | 620
MedSurg | Instruments |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 328 | 504 | 841 | 965
MedSurg | Instruments | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 249 | 399 | 659 | 764
MedSurg | Instruments | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 79 | 105 | 182 | 201
MedSurg | Endoscopy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 316 | 480 | 771 | 950
MedSurg | Endoscopy | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 253 | 383 | 617 | 759
MedSurg | Endoscopy | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 63 | 97 | 154 | 191
MedSurg | Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 632 | 542 | 1,219 | 1,073
MedSurg | Medical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 454 | 430 | 908 | 846
MedSurg | Medical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 178 | 112 | 311 | 227
MedSurg | Sustainability |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 48 | 75 | 115 | 140
MedSurg | Sustainability | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 48 | 75 | 114 | 139
MedSurg | Sustainability | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 0 | 0 | 1 | 1
Neurotechnology and Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 546 | 776 | 1,290 | 1,515
Neurotechnology and Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 339 | 534 | 836 | 1,042
Neurotechnology and Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 207 | 242 | 454 | 473
Neurotechnology and Spine | Neurotechnology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 369 | 484 | 852 | 953
Neurotechnology and Spine | Neurotechnology | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 211 | 313 | 512 | 613
Neurotechnology and Spine | Neurotechnology | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 158 | 171 | 340 | 340
Neurotechnology and Spine | Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 177 | 292 | 438 | 562
Neurotechnology and Spine | Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 128 | 221 | 324 | 429
Neurotechnology and Spine | Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 49 | $ 71 | $ 114 | $ 133

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsDomain
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SustainabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_NeurotechnologyAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |